Qingyi
Qingyi Huang, Shenzhen CN
Patent application number | Description | Published |
---|---|---|
20130335862 | OVERVOLTAGE PROTECTION SYSTEM FOR POWER SYSTEM WITH MULTIPLE PARALLEL-CONNECTED SWITCHING POWER SUPPLIES - An OVP system which includes a plurality of OVP circuits coupled to respective parallel-connected switching power supplies. Each OVP circuit comprises a bus voltage overvoltage detection circuit having a first output which toggles when the voltage on the common power bus exceeds a reference voltage, a modulation flag detection circuit which receives a value that varies with a parameter associated with the PWM or PFM drive signals generated for the switching power supply to which the OVP circuit is coupled and has a second output which toggles when the parameter value exceeds a reference parameter value, logic circuitry which toggles an output when both the first and second outputs toggle, and an overvoltage response circuit which initiates a course of action such as latching or shutting down the switching power supply to which the OVP circuit is coupled when the logic circuitry's output toggles. | 12-19-2013 |
20140254206 | REVERSE CURRENT CONTROL FOR AN ISOLATED POWER SUPPLY HAVING SYNCHRONOUS RECTIFIERS - In certain example embodiments, a system is provided that includes a circuit. The system also includes a reverse current control module that provides an isolated power supply in order to protect one or more devices in a power chain during one or more testing activities having one or more requirements. | 09-11-2014 |
20140268890 | WIDE OUTPUT VOLTAGE RANGE SWITCHING POWER CONVERTER - A switching power converter includes a voltage source that provides an input voltage Vin to an unregulated DC/DC converter stage and at least one buck-boost converter stage to produce a desired output voltage Vout. The unregulated DC/DC converter stage is adapted to provide an isolated voltage to the at least one regulated buck-boost converter stage, wherein the unregulated DC/DC converter stage comprises a transformer having a primary winding and at least one secondary winding and at least one switching element coupled to the primary winding. The at least one buck-boost converter stage is arranged to operate in a buck mode, boost mode or buck-boost mode in response to a mode selection signal from a mode selection module. By influencing the pulse width modulation output power controller the at least one buck-boost converter stage is arranged to produce one or multiple output voltages. | 09-18-2014 |
20150036390 | SYNCHRONOUS RECTIFIER CONTROL FOR A DOUBLE-ENDED ISOLATED POWER CONVERTER - An apparatus comprises a power converter circuit and a control circuit. The power converter circuit includes a primary circuit side and a secondary circuit side. The primary circuit side includes a plurality of primary switches, and the secondary circuit side includes a plurality of synchronous rectifiers and an inductor. The control circuit is configured to operate the synchronous rectifiers synchronously with the primary switches when inductor current at the inductor is greater than or equal to a reference inductor current, and operate the synchronous rectifiers in a bidirectional mode when the inductor current is less than the reference inductor current, wherein energy is delivered from the primary side to the secondary side and from the secondary side to the primary side during the bidirectional mode. | 02-05-2015 |
Qingyi Li, Jiangshu CN
Patent application number | Description | Published |
---|---|---|
20110263897 | PREPARATION METHOD OF HIGH-PURITY L-CARNITINE - The present invention relate to a preparation method of high-purity L-carnitine which belongs to an important technique of quality control in different steps of chiral medicine production. The method comprises the following steps of: monitoring the content of the L-isomer impurity in chiral material S-epichlorohydrin by gas chromatography and chiral column and controlling the content of the L-isomer impurity in chiral raw material in the definite range; monitoring and controlling the specific optical rotation of the chiral intermediate L-3-chloro-2-hydroxy-N,N,N-trimethyl-propanaminium in the definite ranges using a polarimeter; monitoring the content of the R-isomer in the intermediate L-3-cyano-2-hydroxy-N,N,N-trimethyl-propanaminium using derivation agent (+)α-methyl-6-methoxy-2-naphthaleneaceyl chloride by HPLC and controlling the content of the isomer in the intermediate in the definite range; and measuring the final product L-carnitine using derviation agent (+)α-methyl-6-methoxy-2-naphthaleneaceyl chloride by HPLC. This method gives the high-purity L-carnitine in which the content of L-isomer may be more than 97% and that of R-isomerless than 2%. | 10-27-2011 |
20110281293 | PREPARATION AND ITS USE OF DERIVATIZATION REAGENT FOR DETECTING L-CARNITINE OR D-CARNITINE - A preparation method and its use of derivatisation reagent for detecting L-carnitine or D-carnitine are provided. The present reagent is stable. It can be used for detecting L-carnitine or D-carnitine accurately and sensitively. That is to say, the reagent is applied to detecting the amount of synthesized or natural L-carnitine and the amount of mixing D-carnitine. The compound reagent is used for determining the chiral isomers of chemicals, biological reagents, health care reagents, cosmetic, body fluids and various foods, which contain L-carnitine or/and D-carnitine, and optical isomers of other chiral amino acids. | 11-17-2011 |
Qingyi Li, Somerville, MA US
Patent application number | Description | Published |
---|---|---|
20140206650 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL - This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions. | 07-24-2014 |
Qingyi Zhang, Liaoning CN
Patent application number | Description | Published |
---|---|---|
20130287812 | anti-HPV drug and its application in preparing medicines for treatment of HPV (human papilloma virus) infection - This invention disclosed an anti-HPV drug and its applications in preparing medicines for treatment of HPV (human papilloma virus) infection. This drug was characterized by using human rabies vaccine as its active ingredient and being produced by adding pharmacologically acceptable carriers. This invention also disclosed drug applications in preparing medicines for treatment of HPV infection, i.e. new applications of human rabies vaccines for preparing medicines against HPV infection. The anti-HPV drug described in this invention (i.e. human rabies vaccine) had obvious treatment effects on HPV infection. According to the animal tests and preclinical observation, this drug provided satisfactory and beneficial effects and had the characteristics of safety, effectiveness and nearly no recurrence after treatment; the negative-conversion rate in patients with positive HPV-infection reached 90% after treatment. | 10-31-2013 |